A chronic dosing study to elucidate longer duration treatment of exendin 9-39 in patients with post-bariatric hypoglycemia (PBH).

Trial Profile

A chronic dosing study to elucidate longer duration treatment of exendin 9-39 in patients with post-bariatric hypoglycemia (PBH).

Planning
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Exendin 9 (Primary)
  • Indications Hypoglycaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Dec 2016 New trial record
    • 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, company has filed an investigational new drug (IND) application with the FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top